Receive a copy of our current research models and services product guide.
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Search by therapeutic area, research phase, and products and services at inotiv.com.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
November 3-7, 2024 Nashville, TN Booth #1414 Each fall since 1950, the American Association for Laboratory Animal Science has held its annual National...
November 14-19, 2024 Washington, D.C. Booth #2940 Inotiv is excited to contribute to this vibrant community, advancing drug development with innovative solutions for better patient...
November 13, 2024 1:00 PM - 2:30 PM Eastern Time From vascular stents to dental implants, many medical devices work by being temporarily or permanently placed in the human bod...
September 16, 2024 WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Comp...
September 6, 2024 Inotiv is pleased to announce that our Talent Acquisition team has been selected as one of ...
August 28, 2024 WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a lead...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2024 Inotiv. All Rights Reserved.